CONTINEUM THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.5 USD | +3.61% |
|
-1.96% | 0.00% |
| Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
| Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 376 | - | - |
| Enterprise Value (EV) 1 | 172.3 | 316.2 | 306.4 |
| P/E ratio | - | - | - |
| Yield | - | - | - |
| Capitalization / Revenue | - | 25.1 x | - |
| EV / Revenue | - | 21.1 x | - |
| EV / EBITDA | -3.98 x | -6.79 x | -4.27 x |
| EV / FCF | -4.66 x | -7.53 x | -4.51 x |
| FCF Yield | -21.5% | -13.3% | -22.2% |
| Price to Book | - | -8.42 x | 6.71 x |
| Nbr of stocks (in thousands) | 25,131 | - | - |
| Reference price 2 | 15.50 | 15.50 | 15.50 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | 15 | - |
| EBITDA 1 | - | -43.33 | -46.6 | -71.78 |
| EBIT 1 | - | -45.95 | -40.9 | -80.07 |
| Operating Margin | - | - | -272.64% | - |
| Earnings before Tax (EBT) | 23.17 | - | - | - |
| Net income | 22.72 | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -42 | -68 |
| FCF margin | - | - | -280% | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/15/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -9.93 | -9.5 | -12.6 | -15.7 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/16/24 | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 204 | 59.7 | 69.5 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | - | -37 | -42 | -68 |
| ROE (net income / shareholders' equity) | - | - | - | -663% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share 2 | - | - | -1.840 | 2.310 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | 0.43 | 0.35 | 0.55 |
| Capex / Sales | - | - | 2.34% | - |
| Announcement Date | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14.96
USD
Average target price
28
USD
Spread / Average Target
+87.17%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 376M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- CTNM Stock
- Financials Contineum Therapeutics, Inc.